Faruk Tunahan Korkmaz – Trademark Portfolio
Entity Type: 01
Faruk Tunahan Korkmaz owns a portfolio of 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as VIOLAV, VIOLAURA, and YARNALOT. Of these, 3 are registered and 1 is pending. The portfolio spans 5 Nice Classification classes, led by Class 35 (Advertising & Business) and Class 3 (Cosmetics & Cleaning). Headquartered in New York, NY.
7802 37TH AVE JACKSON HEIGHTS
New York, NY 11372
Showing of trademarks Trademarks
Trademark Classifications
Faruk Tunahan Korkmaz's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Leather and imitations of leather; animal skins, hides; trunks and travelling bags
Frequently Asked Questions
How many trademarks does Faruk Tunahan Korkmaz have?
Faruk Tunahan Korkmaz has 7 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending, 3 abandoned.
What trademark classes does Faruk Tunahan Korkmaz file in?
Faruk Tunahan Korkmaz files trademarks across 5 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 3 (Cosmetics & Cleaning), Class 20 (Furniture), Class 18 (Leather Goods), Class 23 (Yarns & Threads). Class 35 covers advertising; business management; business administration; office functions.
What are Faruk Tunahan Korkmaz's most well-known trademarks?
Faruk Tunahan Korkmaz's registered trademark portfolio includes well-known marks such as VIOLAV, VIOLAURA, and YARNALOT. These are among 3 currently registered trademarks in the portfolio.
What is Faruk Tunahan Korkmaz's trademark registration success rate?
Faruk Tunahan Korkmaz has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 1 application is pending review.